New Heart Disease Blood Test that Detects Silent Killer Sweeps North America
GD Biosciences, developer of the Cardiac PULS Test which detects evidence of heart disease in asymptomatic individuals and predicts their risk of a future coronary event with unparalleled accuracy, capped off a momentous week in the news.
The heart disease assessment test was featured coast-to-coast in the U.S., including television segments in Los Angeles, Austin, Texas, Minneapolis, Minn. and Philadelphia, while reaching multiple provinces in Canada, with appearances in The Province, Saskatoon StarPhoenix and Times Colonist.
“This test is a monumental step forward in combatting the world’s deadliest killer heart disease,” said Dr. Douglas Harrington, CEO of California-based GD Biosciences. “The ability to identify underlying silent cardiac disease and predict the likelihood of a cardiac event before it happens is crucial in the health of a patient, especially those who are not showing any symptoms.”
Dr. Harrington adds that current measures, like cholesterol levels, are insufficient to identify an individuals cardiac health. Multiple studies have shown that roughly 50 percent of heart attack victims had normal cholesterol levels. Most people don’t realize they have problem until they experience either a heart attack or sudden death.
PULS, an acronym for Protein Unstable Lesion Signature, is a simple blood test that analyzes the proteins secreted from active lesions in the coronary arteries. Measured with other factors including age, race and gender, as well as in conjunction with current testing practices, the heart disease assessment test is able to identify underlying silent cardiac disease activity and predict the likelihood of a future cardiac event within a five year window.
“The momentum that the PULS Test is building has been incredible as we look to introduce it to more and more markets around the world,” added Harrington, who recently presented the medical breakthrough at the 20th World Congress on Heart Disease in Vancouver, British Columbia. “We know the test saves lives, it has done so numerous times already, now it’s just making people aware of their options and expanding accessibility.”
For more information, take a look at the Cardiac PULS Test’s recent news stories:
Times Colonist – Blood test can assess heart attack risk, conference told
Saskatoon Star Phoenix – New test for heart attack risk
My Fox Philly – Technology helps predict heart attacks
KTTV – LA – Technology helps predict heart attacks
Good Day Austin – Technology helps predict heart attacks
About Douglas Harrington, MD
Dr. Douglas Harrington has over 30 years of experience in the research, development, commercialization, and expansion of innovative healthcare technology and services. As former President and Lab Director of Nichols Institute, Dr. Harrington expanded their molecular genetics, infectious disease, immunology, cytogenetic, and anatomic pathology offerings.
Dr. Harrington holds a number of patents including automated image analysis of residual cancer protein, catalytic heavy metal extraction, and biomarker assays for diagnosis and classification of cardiac disease. He has been involved as director or founder of multiple startup companies – from devices to molecular genetics focusing on immunology, cancer and cardiology, where he has taken a number of new molecular technologies through state and federal regulatory approval.
In addition to being the CEO & Lab Director of Global Discovery Biosciences (GD Biosciences), Dr. Harrington is a Clinical Professor of Pathology at the USC Keck School of Medicine, a published author of numerous peer-reviewed papers, and a sought after speaker in the area of preventive medicine.
About GD Biosciences
Global Discovery Biosciences is a pioneer in the field of diagnostic medicine. The company works on the cutting edge of medical research, turns discoveries into innovative products and brings those products to the global marketplace.
The company works with advanced research teams to develop, manufacture and distribute innovative technology platforms to address the needs of the global disease burden. Its CLIA-certified and GMP laboratory performs a menu of clinically effective tests targeting key health issues. Our goal is to equip physicians with the tools they need to transform health care – one patient at a time.
The Publicity Agency